INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary brain tumor, characterized by diffuse infiltration into surrounding healthy brain tissue. 1 Patients with a malignant glioma have poor prognosis owing to local recurrence, with a 5-year survival of only 9.8% despite surgery, radiotherapy and temozolomide (TMZ) chemotherapy. 2 These facts stress the need for more effective novel therapeutic strategies.
There is growing evidence showing that tumors are driven by a rare fraction of tumor cells named cancer stem cells (CSCs) . 3 This population of cells has been identified in different solid malignancies, including GBM. 4 In analogy to normal stem cells, CSCs are also capable of self-renewal and multipotency. 5 In addition to these hallmarks of stemness, CSCs are suggested to further possess active anti-apoptotic pathways, efficient DNA damage repair and the expression of multidrug transporters on the plasma membrane, making them highly resistant to conventional therapies. 6, 7 It is thus believed that they are the cause of tumor recurrence. Therefore, it is important to identify the factors responsible for sustaining this population of cells.
Induction of angiogenesis is an essential prerequisite for tumor growth and progression. Once tumors reach a certain size (E1 mm 3 ), simple diffusion of oxygen and nutrients is not sufficient to supply all tumor cells with necessary factors. This results in hypoxic areas, which trigger the formation of tumor vasculature, termed the angiogenic switch. This way the tumor establishes its own independent blood supply, which consequently facilitates its further expansion. GBMs are one of the most vascularized human cancers, and the formation of tumorassociated vessels occurs early during tumor progression. In fact, endothelial proliferation is one of the pathological criteria for grading a glioma as high grade, indicative of a poor prognosis. 8 As development of tumor vasculature is an essential component of tumor progression, tumor blood vessels have been a target of novel therapeutics. The neutralizing anti-VEGF antibody Bevacizumab is currently in a phase III non-randomized trial for recurrent GBM. Initial results show that this treatment slightly improves the overall survival of GBM patients compared with chemotherapy alone. This effect is probably due to transient normalization of tumor vasculature, resulting in enhanced delivery and efficacy of cytotoxic agents. 9, 10 In addition to supplying tumor cells with oxygen and nutrients, endothelial cells are believed to form a niche-type entity in GBM. Evidence so far shows that endothelial cells indeed closely interact with brain CSCs and maintain them in a stem-like state. 11 Vice versa, GBM CSCs are able to recruit endothelial cells by secreting VEGF, stimulating the formation of their own niche. 12 Moreover, two recent reports indicate that GBM CSCs can differentiate into cells that very closely resemble tumor-associated vascular endothelial cells, 13, 14 suggesting that GBM CSCs can differentiate into niche-type cells. Therefore endothelial cells have a major role in tumor growth, and it is thus necessary to obtain knowledge on how treatment changes vascular function and subsequently their interaction with CSCs. However, observations on radiosensitivity of endothelial cells vary considerably. It has been reported that the main response of tumor endothelial cells to irradiation is massive apoptosis and that this is dependent on the acid sphingomyelinase pathway. 15 For GBM CSCs, this would implicate partial eradication of their supportive niche after irradiation, leaving them unprotected and potentially more susceptible to treatment. On the other hand, different reports state that endothelial cells, such as human umbilical vein endothelial cells (HUVECs), mainly undergo senescence when irradiated. 16 Here we re-evaluated these claims, especially in the context of the tumor microvascular endothelial cells (tMVECs) and their potential role as a protective niche for CSCs during therapy. We previously developed a method to coisolate CSCs and tMVECs from human GBM specimens, which enabled us to reconstruct the physiological environment of GBM cells. 17 Our data show that, when co-culturing these cells, tMVECs are capable of stimulating growth and stemness of GBM cells despite radiation and TMZ treatments. This is enabled primarily by their extensive cell death resistance to both therapies. Although TMZ treatment had no effect on these cells, their preferential response to irradiation is irreversible senescence. Senescent tMVECs can still support CSC growth, with the same capacity as non-senescent ones. Moreover, GBM cells have the ability to differentiate into cells that phenocopy tMVECs, at least in some aspects, most important being senescent state upon radiation and support of GBM growth. This could, at least partially, explain therapy resistance and recurrence of GBM.
RESULTS

CD133
þ fraction of GBM cells is enriched for CSCs GBM CSCs were isolated from the tumor material of GBM patients who underwent surgical resection. These cells can be propagated in culture as spheroids, resulting in the expansion of CD133 þ CSCs (Figure 1a) . Consistent with previously published data, the CD133 þ tumor cells had high clonogenic capacity (Figure 1b ). 4 Furthermore, as shown before, the CD133 þ GBM cells were tumorigenic and gave rise to invasive, scattered tumors upon injection, whereas CD133
À cells did not ( Figure 1c and Supplementary Figure 1a) . This confirms that the CD133 þ fraction is enriched in GBM CSCs.
Irradiation combined with TMZ is standard therapy for GBM patients. We therefore first exposed our GBM cultures to these treatments in order to investigate their sensitivity. GBM spheroid cultures showed an increased amount of cell death when irradiated with 1 Â 5 Gy, although the level of sensitivity varied between cultures (Figure 1d ). The two lines shown display the most extreme response to radiotherapy when looking at cell death. In G073, only a very limited amount of apoptosis is observed, whereas apoptosis was induced in a large fraction of the G408 cells. In Supplementary Figure 3 , several other GBM spheroid cultures are shown with varying response to irradiation. In the following experiments, we mainly focused on two independent spheroid cultures isolated from different patients (G408 and The role of tumor vasculature in GBM therapy resistance T Borovski et al G073). Both these lines appeared to be resistant to the alkylating agent TMZ, whereas a third line G077 was extremely sensitive to TMZ (Supplementary Figure 1b) .
tMVECs support the growth of GBM CSCs despite irradiation and TMZ treatment In addition to GBM CSCs, we also co-isolated tMVECs from GBM specimens. These cells expressed endothelial markers CD31 and CD105, and demonstrated tube-forming ability ( Supplementary  Figures 2a and b) . Previously we showed that tMVECs support the expansion and stemness of GBM cells. 17 Here, we investigated whether these stimulatory effects of tMVECs were preserved after irradiation or chemotherapy. As shown in Figure 2a , tMVECs induced expansion of GBM cells even after irradiation with 1 Â 5 Gy. The inhibition of proliferation upon irradiation in the absence of tMVECs differs between GBM lines (Figure 2a and Supplementary Figure 3a) , but in all cases the tMVECs enhance proliferation. In other words, tMVECs protect GBM cells in part from the effects of irradiation. Moreover, we determined the CD133 expression of GBM cells after exposure to 1 Â 5 Gy in the absence or presence of tMVECs. Co-culture strongly increased the CD133 þ fraction in GBM cells, suggesting that tMVECs support stemness in CSC cultures. Importantly, this enhanced CD133 positivity was preserved after irradiation ( Figure 2b and Supplementary Figure 3b) . Thus, in addition to enhancing their expansion, tMVECs are able to provide factors that support CSCs to preserve their 'stemness', even upon irradiation.
The tMVEC-induced increase in GBM cell numbers after irradiation could result from reduced cell death, increased proliferation or a combination of both. The dilution of carboxyfluorescein succinimidyl ester (CFSE), measured 4 days after the beginning of the experiment, demonstrated that GBM cells had higher proliferation rates in co-culture as compared with control samples (lower mean fluorescence intensity means higher proliferation). Furthermore, when co-cultured with tMVECs, GBM cells recovered much faster from the irradiation treatment and reentered the cell cycle ( Figure 2c and Supplementary Figure 3c) . Moreover, the amount of irradiation-induced cell death of GBM cells was in most cases lower in co-culture as compared with control-irradiated cells ( Figure 2d and Supplementary Figure 3d) . The protective effect of tMVECs varied between GBM lines. Recently, GBM subtypes that differ in the presence of signalingpathway alterations as well as in their response to therapy have been identified. 18 The protective and proliferation-enhancing effect of tMVECs on GBMs is mediated by soluble and cellbound factors. 17 It is thus likely that the dependence on certain signaling pathways and presence of receptors on different GBM subtypes determine the effects of their interaction with tMVECs.
We next tested whether tMVECs can protect GBM cells from treatment with the chemotherapeutic agent TMZ. The TMZsensitive GBM line G077 showed a significantly higher cell number under TMZ treatment when co-cultured with tMVECs as compared with the control, indicating that TMZ-sensitive CSCs are protected by tMVECs from chemotherapy as well (Supplementary Figure 3e) . Moreover, under combined TMZ and radiation treatment, tMVECs also exert protective effects on these GBM cells (Supplementary Figure 3e) . The underlying mechanism is unknown, but it has been reported that the response of GBM patients to TMZ treatment largely depends on whether MGMT gene is silenced or not. 19 Thus, it can be speculated that tMVECs might regulate MGMT levels in tumor cells or simply enhance the repair machinery necessary to deal with the damage induced by TMZ. Combined, our data demonstrate that tMVECs not only increase the basal proliferation level of GBM cells, but also provide additional protective effects from radio-and chemotherapy.
Endothelial cells undergo senescence after irradiation As the effects of co-culture on GBM CSCs were still evident after treatment, we decided to investigate the response of tMVECs to these treatments. Cells were exposed to 1 Â 5 Gy or 1 Â 15 Gy g-irradiation and the amount of cell death was determined, with HUVECs serving as control. Propidium iodide (PI) exclusion revealed a very low amount of cell death after irradiation in two separate tMVEC lines, E030 and E023, whereas HUVECs showed higher cell death rates under these conditions (Figure 3a and Supplementary Figure 4a) . Even after high-dose radiation with 1 Â 15 Gy, we detected only B5% of cell death in our tMVEC cultures, indicating that apoptosis is not a major response and that the vast majority of cells survived the treatment. This was consistent with other cell death measurements, such as DNA fragmentation by Nicoletti assay, YO-PRO and Annexin V staining, which consistently showed low death rates (Supplementary Figure 4b and data not shown). Moreover, we exposed tMVECs to different doses of TMZ. PI exclusion showed that after TMZ treatment no cell death could be detected (Supplementary Figure 4c) . Analysis of the cell cycle distribution also revealed no change in cell cycle profile after the treatment with this alkylating agent (Supplementary Figure 4c) . Thus, we conclude that tMVECs are highly resistant to TMZ, in addition to irradiation.
Importantly, the DNA analysis revealed that the tMVECs appeared to undergo G 2 arrest after irradiation (Supplementary Figure 4b) . To further determine the cell cycle distribution of tMVECs before and after treatment, we performed a BrdU incorporation assay. The results show that irradiation decreased the amount of proliferating cells in a dose-dependent manner, indeed mainly due to G 2 arrest (Figure 3b and Supplementary  Figure 4a) . Even a week after irradiation, cells remained growtharrested and did not resume proliferation (Figure 3b and Supplementary Figure 4a) . Furthermore, we noticed a dramatic change in the light-scatter properties of the surviving tMVECs after irradiation (Supplementary Figure 4d) . Senescence is known to be an irreversible cell cycle arrest, associated with morphological changes of the cells, in which the cells get significantly larger, show flattened shape and express senescence-associated bgalactosidase. To determine whether senescence was the preferential response of tMVECs to irradiation, we performed a b-gal assay. This assay confirmed a significant increase in the amount of senescent cells after treatment (Figure 3c and Supplementary Figure 4e) . Accordingly, irradiated tMVECs also displayed increased levels of the cyclin-dependent kinase (CDK) inhibitor p16, for which elevated expression was associated with senescence ( Figure 3d ). 17, 20 In an endeavor to validate whether senescent endothelial cells can also be detected upon irradiation in vivo, we examined brains of nude mice that were exposed to 20 Gy of irradiation and compared them with non-irradiated ones (Figure 3e ). Co-staining for the senescence marker b-gal and the endothelial marker CD31 revealed that senescent endothelial cells can exclusively be detected in irradiated brains. None of the endothelial cells were senescent in the non-irradiated brains, indicating that senescence is a consequence of the radiation treatment. Moreover, we examined post-mortem biopsies of a GBM patient who displayed tumor recurrence after having received treatment with surgery and subsequent radiotherapy (60 Gy). As this effectively represents an irradiated tumor, these post-mortem samples were analyzed for the presence of senescent tMVECs. We clearly detected tMVECs that were co-stained for b-gal pointing to senescence (Figure 3f and Supplementary Figure 4f) . Quantification of senescent cells within this patient sample revealed that the majority of the senescent cells (470%) were of endothelial origin as determined by CD105 staining. Moreover, this revealed that around 30% of the endothelial cells in this tumor sample was stained for b-gal and thus was considered senescent.
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GBM can differentiate into cells that mimic tMVECs in their radiation response and support of GBM expansion It has been reported recently that GBM cells have the ability to differentiate into endothelial-like cells. 13, 14 This suggested that GBM cells could effectively generate their own niche by differentiating into an endothelial-like phenotype that would support the CSC fraction in the tumor. To test whether this is indeed the case, we allowed our GBM cultures to differentiate under conditions described to favor the endothelial-like lineage.
The resulting cells, which we termed endothelial-like GBM (E-GBM) to reflect this phenotypical change, indeed resemble, at least in some aspects, endothelial cells. In a tube-formation assay, E-GBMs had the ability to form vessel-like structures, similar to tMVECs ( Supplementary Figures 2 and 5 ). To determine whether the E-GBMs show a similar radiation response as tMVECs, we exposed them to g-irradiation. Strikingly, the results show minimal cell death of E-GBMs, in contrast to the response observed with the undifferentiated parental GBM-CSC cultures (Figure 5a ). This effect was evident even in the initially highly radiosensitive G408 cells that reverted to complete resistance to this treatment upon E-GBM differentiation (Figure 5a) . Accordingly, the preferred response of E-GBMs to irradiation rather seemed to be senescence (Figure 5b ). It is interesting to note that senescence seems to be a default response for these E-GBMs and in some cases is already observed in a significant fraction of the non-irradiated cells (E-G081). This is in line with previous observations showing that GBM-associated endothelial cells undergo senescence. 21 The observed differences in basal senescence in the different isolates of E-GBM may reflect different GBM subtypes. 18 However, the resistance to radiation and the induction of senescence is a common feature for all E-GBMs tested. Most strikingly, co-culture of E-GBMs, both non-irradiated and irradiated, led to a significant The role of tumor vasculature in GBM therapy resistance T Borovski et al increase in the number of GBM-CSCs, suggesting that E-GBMs are also capable of supporting the growth of GBM-CSCs comparable to tMVECs (Figure 5c ). Importantly, this was observed for various GBM cultures. Combined, our data therefore point to a general tumor-supportive role for both tMVECs and E-GBMs that is sustained after irradiation.
DISCUSSION
There is a growing body of literature concerning the effects of irradiation and TMZ on GBM cells. However, these data are mainly derived from in vitro studies using GBM cell lines. In addition, recent insights suggested an important role of the tumor microenvironment in tumor maintenance and progression, tumor vasculature in particular, in the case of GBM. 11 The majority of brain tumor vasculature is structurally and functionally different from the vessels in healthy tissue as it is disorganized, tortuous, dilated and often displaying dead-end structures. 22 These seemingly dysfunctional blood vessels still co-localize with tumor cells, the CSC fraction in particular, and form a niche for these cells. Published data demonstrate that tumor microvasculature has an essential role in sustaining GBM CSCs, regulating their self-renewal and promoting their tumorigenicity. 11 However, little is known about the consequences of treatment on these endothelial cells. The ability to isolate these cells from primary tumor material gives us the unique opportunity Figure 5 . GBMs that differentiate into endothelial-like GBMs become radiation resistant and support the expansion of GBM-CSCs. (a) G408, G081 and G008 were either cultured in endothelial differentiation conditions (E-GBM) or maintained under CSC conditions (GBM-CSC) for 5 days, and subsequently were exposed to 1 Â 5 Gy. Cell death was measured by PI exclusion. Graphs show percentages of PI þ cells 5 days after irradiation treatment. Error bars represent s.d. (n ¼ 3) (b). Treatment with g-irradiation preferentially induces senescence in E-GBMs whereas the parental GBM-CSC's response is cell death. b-gal assay was performed on G408, G081 and G008 under conditions as described in panel a. Senescent cells are stained blue. Scale bars 20 mm. (c) E-GBM were co-cultured with CFSE labeled G408, G081 and G008 GBM-CSCs; the numbers of CFSE þ GBM-CSCs were measured using calibrated beads after 4 days of co-culturing. One representative example of two independent experiments is shown. Error bars represent s.d.
The role of tumor vasculature in GBM therapy resistance T Borovski et al to study the effects of various treatments on isolated GBM CSC cultures, alone as well as in the context of their perivascular niche. Ionizing radiation is mostly contributing to survival of GBM patients (B7 months), next to surgery (B5 months) and chemotherapy (B2 months). The effects of ionizing radiation on angiogenesis in both tumors and healthy tissues have long been a matter of considerable debate and still remain largely elusive. At the cellular level, apoptosis of endothelial cells is believed to be the main biological process underlying irradiation-induced endothelial dysfunction, and this is thought to be dependent on the acid sphingomyelinase pathway. 15 Our data, however, show that the endothelial cells are highly resistant to radiation treatment and that their main response to radiation is irreversible cell cycle arrest, senescence (Figure 3 and Supplementary Figure 4) . Our results are in agreement with the observations of Garccia-Barros et al., 15 who reported low cell death rates of endothelial cells at doses of irradiation up to 15 Gy, and strong increase in apoptotic cells at higher doses. Here we extend these observations by showing that the majority of the surviving endothelial cells undergo senescence instead of cell death. Accordingly, HUVECs exposed to g-irradiation are also prone to become senescent. 16 Importantly, senescent endothelial cells can be exclusively detected in mice brains upon irradiation treatment, whereas none of these cells were found in non-irradiated brains (Figure 3e) , strongly suggesting the senescent state of these cells to be the result of treatment itself. In addition, senescent tMVECs can also be detected in irradiated GBM samples (Figure 3f ). This is consistent with previous reports stating that glioma-associated endothelial cells exhibit characteristics of cellular senescence, particularly in central parts of the tumor. 21 More importantly, these senescent tumor endothelial cells seem to be more resistant to cytotoxic drugs and produce even more growth factors as compared with normal vasculature in the brain. 21 Senescent cells, even though terminally arrested, are still metabolically active and able to secrete different growth factors, cytokines, immune modulators and enzymes, all of which can alter tissue microenvironment and as such could potentially create a tumor microenvironment that harbors and supports cancer cells. [23] [24] [25] Accordingly, senescent fibroblasts have already been shown to sustain growth of epithelial tumor cells and furthermore promote their tumorigenicity. 26, 27 Here we show that senescent endothelial cells are fully capable of supporting the expansion of GBM cells while maintaining the CSC fraction, with the same capacity as nonsenescent tMVECs (Figure 4) . Moreover, this supportive effect is still evident after irradiation treatment (Figure 2 and Supplementary Figure 3 ). Even though GBM cells will undergo cell death upon irradiation and show reduced proliferation, tMVECs provide support to overcome this irradiation response. Importantly, it has been reported before that CD133 þ GBM are more resistant to cell death induction by irradiation. In our in vitro experiments we do not observe a selective increase in the number of CD133 þ cells upon irradiation, arguing against resistance of these cells. However, this experiment runs over a 5-day period, during which CSCs divide and may yield new CD133
À cells, potentially reestablishing the original ratio between CD133 þ and CD133 À cells. Using this set-up, it is therefore difficult to conclude whether CSCs are more resistant to irradiation treatment. tMVECs also provide protection of GBM cells against TMZ treatment, as well as against an even more cytotoxic combination of g-irradiation with chemotherapy (Supplementary Figure 3e) . Furthermore, we show that GBM cells can differentiate into cells that mimic some aspects of the tumor endothelial phenotype (E-GBM) as they become radioresistant upon differentiation and preferentially enter senescence. This is comparable to genuine tMVECs and in contrast to the radiosensitive parental GBM cells (Figures 5a and b) . More importantly, E-GBMs share with tMVECs the capability to support the survival and expansion of GBM-CSCs after g-irradiation, the first-line treatment for GBM. These results suggest a striking scenario in which the tumor cells could potentially provide themselves with an environmental niche that allows them to survive and even proliferate during and after treatment with g-irradiation and alkylating agents. Such a protective niche could contribute to the observed tumor relapse after an initial clinical response.
Disrupting the interaction between tumor and its vascular niche would negate the protective effects for tumor cells and potentially sensitize them to treatment with DNA-damaging agents. The molecules that mediate this interaction are thus attractive therapeutic targets that could help to develop novel strategies to fight this disease.
MATERIALS AND METHODS
Isolation of tMVECs and CSCs
GBM and tMVECs were essentially isolated as described. 17 In short, GBM specimens were cut into small pieces and digested in 1 mg/ml Liberase-1 (Roche, Woerden, The Netherlands) for 10 min at room temperature (RT). The cell suspension was passed through a 70-mm cell strainer (BD, Erembodegem, Belgium). The flow-through containing the GBM cells was washed in CSC medium and cultured as described below. The tMVECs contained in the filter residue were further digested in 0.05 U/ml Collagenase/Dispase (Roche) for 60 min at 37 1C, constantly agitated, and furthermore filtered through a 40-mm cell strainer (BD) to remove undigested tissue components. The flow-through containing the tMVECs was washed in Iscove's Modified Dulbecco's Medium (IMDM) with 10% fetal calf serum (FCS) and cultured as described below. Patient specimens were obtained according to established and approved protocols.
Cell culture GBM CSCs were cultured in advanced Dulbecco's Modified Eagle Medium (DMEM)/F12 medium (Invitrogen, Bleiswijk, The Netherlands) supplemented with 2 mM glutamine, 0.3% glucose, N2 supplement (Invitrogen), 100 mM b-mercaptoethanol, Trace-Elements B and C (VWR, Amsterdam, The Netherlands), 5 mM HEPES, 2 mg/ml heparin, lipid mixture (Sigma, Zwijndrecht, The Netherlands), 25 mg/ml insulin, 50 ng/ml h-bFGF and 20 ng/ml h-EGF (Peprotech, London, UK) in ultra-low attachment flasks (Corning, Amsterdam, The Netherlands). This will further be referred as CSC medium. Growth factors were supplemented twice weekly and spheroids were dissociated weekly with Accutase (Sigma). tMVECs and HUVECs (Promocell, Heidelberg, Germany) were cultured in Endothelial Cell Growth Medium MV2 (Promocell) on gelatine-coated plates (0.2% gelatine, 2 h at 371C). In order to differentiate GBM cells into endothelial-like phenotype, cells were plated on gelatine-coated plate or growth factor reduced matrigel (BD) in Endothelial Cell Growth Medium and incubated for 5 days.
Intracranial cell transplantation into nude mice GBM cultures were stained for CD133 as described below, sorted for 10% of the highest CD133 þ and 10% of the CD133 À , and resuspended in 3 ml PBS containing 5 Â 10 3 cells. Aliquots were injected into the frontal cortex of 5-to 8-week-old female nude mice following inhalation of general anesthesia. All animal experiments were approved by the local animal-welfare committee.
Mouse brain fixation
Mice brains were immediately removed from killed mice and fixed in 4% formaldehyde. After fixation, samples were dehydrated by ethanol steps and embedded in paraffin. Brains were sectioned at 6 mm thickness and stained for Ki67 as described below.
Senescence-associated b-galactosidase (SA-b-gal) assay Cells were fixed in 0.2% glutaraldehyde for 5 min at RT, washed with PBS, and incubated overnight at 37 1C in a phosphate buffer pH6 containing 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 150 mM NaCl and 1 mg/ml X-gal (Fermentas, St Leon-Rot, Germany). Cultures were assessed for SA-bgal content using light microscopy.
Tube formation assay
Growth factor reduced matrigel (BD) was thawed on ice, 500 ml per well was added in 24-well plate and incubated at 37 1C for 30 min to allow
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Limiting dilution assay (LDA)
Cells were deposited by FACS sorting into ultra-low adhesion 96-well plates (Corning) containing CSC medium. Different lines were plated in different dilutions depending on their clonogenicity, from complete saturation (all wells contained spheres) to complete dilution (none of the wells contained spheres). Plates were scored after 2 weeks. Medium was refreshed every 3 days. Frequency of clonogenic cells was calculated using ELDA software: http://bioinf.wehi.edu.au/software/elda/index.html
Co-cultures and measuring absolute cell numbers tMVEC were grown in 12-well plates in Endothelial Cell Growth Medium until confluence. GBM CSCs were dissociated into single cell suspension and labeled with CFSE (0.5 mM CFSE in PBS for 10 min at 37 1C, Molecular Probes, Bleiswijk, The Netherlands) to be distinguishable from tMVECs. 5 Â 10 3 GBM CSCs were added to each well containing growth-factor free CSC medium, either with or without tMVECs. Next day cells were irradiated with 1 Â 5 Gy g-irradiation using Cs 137 source. Dosage rate was approximately 0.8 Gy/min. TMZ (Sigma) was diluted in dimethyl sulfoxide, added same day as cells were irradiated (10, 50 or 100 mM TMZ) and refreshed 2 days later. Three days after the irradiation, samples were measured. Determination of absolute cell numbers: samples were resuspended in 200 ml of FACS-buffer (2% BSA/0.01% Na-azide in PBS) containing 1 mg/ml of PI, added to Trucount tubes (BD) containing calibrated beads and cell numbers were determined by FACS, measuring each sample per same number of beads.
Immunocytochemistry
Staining for extracellular markers. Cells were resuspended in FACS buffer containing the antibody and incubated on ice for 30 min. After washing with PBS, FACS buffer containing 1 mg/ml of PI was added to exclude dead cells, and samples were measured by FACS. The antibodies used: CD133.1-APC (Miltenyi Biotec, Leiden, The Netherlands), CD31-PE (BD), CD105-PE (Invitrogen).
Ki67 staining. Brain sections were deparaffinized, antigens were retrieved by boiling in 10 mM sodium citrate buffer pH6 for 10 min, followed by peroxide blocking (1% H 2 O 2 in methanol for 15 min) and serum blocking, after which anti-human Ki67 antibody (Clone SP6, Thermoscientific, Braunschweig, Germany) was added and incubated at 4 1C overnight. For detection Powervision (Immunologic, Duiven, The Netherlands) and DAB solution (DAKO, Enschede, The Netherlands) were used, and slides were counterstained with haematoxylin.
BrdU staining. Cells were incubated with 10 mM BrdU for 1 h at 37 1C and afterwards fixed in 80% ethanol. Staining included 4 steps: cells were incubated in 0.4 mg/ml pepsin/0.1 N HCl solution for 30 min, 2 N HCl for 30 min, rat anti-BrdU antibody (Abcam) and anti-rat Alexa-Fluor 647 antibody (Invitrogen) for 1 h each. First step was performed at RT, the following at 37 1C. Antibodies were diluted in 0.1% Tween-20/PBS. Finally, samples were resuspended in FACS buffer containing 50 mg/ml PI and measured by FACS.
Cell death measurement PI exclusion was done by resuspending the samples in FACS buffer containing 1 mg/ml PI and measuring by FACS. Nicoletti assay was performed by resuspending the samples in Nicoletti buffer (0.1% sodium citrate, pH7.4/0.1% TritonX-100) containing 50 mg/ml PI and keeping them overnight at 4 1C. DNA content was determined on FACS. Sub-G 0 /G 1 was considered apoptotic; the cellular debris was excluded from the analysis. Specific cell death was calculated using formula: 100 Â (% experimental cell death À % spontaneous cell death)/(100 À % spontaneous cell death).
Western blot
Cells were lysed with Triton X-100 lyses buffer, and proteins were separated on a SDS/10% polyacrylamide gel and blotted onto transfer membrane (Immobilone-FL, Millipore, Amsterdam, The Netherlands). Blots were blocked for 1 h at RT in Odyssey blocking buffer LI-COR (Westburg, Leusden, The Netherlands), diluted in PBS 1:1. Blots were incubated with 1 mg/ml anti-p16 antibody (BD) in blocking buffer overnight at 4 1C, in IRDye 680 anti-mouse LI-COR (Westburg, Leusden, The Netherlands) for 1 h at RT and detected using the Odyssey system.
In vivo detection of (senescent) endothelial cells FVB/nude mice received a single local irradiation dose of 20 Gy on the right hemisphere of the brain applied as a 5-mm-wide beam by m-Image Guided Radiotherapy using the X-Rad 225Cx (Precision X-Ray Inc., North Branford, CT, USA). Non-irradiated mice were used as a control. After 7 days, the mice were killed.
Tumor specimen was collected after obtaining written informed consent, in accordance with the Declaration of Helsinki and after approval by the Academic Medical Center Institutional Review Board (EudraCT2007-005644-24/CCMO NL20411.018.07/NTR 1148).
The samples were frozen in carbon dioxide and kept at À 80 1C until further processing. Cryosections were stained with b-gal and CD31/CD105 as follows: fixation and b-gal staining was performed according to the manufacturer's instructions (Millipore KAA0022RF). Upon peroxide blocking (1% H 2 O 2 in methanol for 15 min at RT) and serum blocking, samples were incubated with anti-CD31 (BD, 555444) or CD105 (DAKO, M3527) for 2 h at RT. Powervision anti-mouse-poly HRP (Immunologic) and DAB (DAKO) were used to detect endothelial cells. Nuclei were counterstained with nuclear red and haematoxylin.
Visualization of staining on GBM samples. Multispectral data sets from slides stained for CD105 and b-gal were acquired using a Nuance camera system (Caliper Life Science/CRi, Hopkinton, MA, USA) from 420 to 720 nm at intervals of 20 nm. After loading the DAB, b-gal and haematoxylin spectra obtained from single-staining slides, data sets were spectrally unmixed, allowing for exclusive visualization of stained cells and conversion of colors. Original staining can be viewed in Supplementary  Figure 4f and converted image in Figure 3f .
